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Abstract
The objective of this study was to describe the development and initial psychometric analysis of the UK English version of the Duchenne muscular
dystrophy FunctionalAbility Self-AssessmentTool (DMDSAT), a patient-reported outcome (PRO) scale designed to measure functional ability in patients
with Duchenne muscular dystrophy (DMD). Item selection was made by neuromuscular specialists and a Rasch analysis was performed to understand
the psychometric properties of the DMDSAT. Instrument scores were also linked to cost of illness and health-related quality of life data. The administered
version, completed by 186 UK patient–caregivers pairs, included eight items in four domains: Arm function, Mobility, Transfers, and Ventilation status.
These items together successfully operationalized functional ability in DMD, with excellent targeting and reliability (Person Separation Index: 0.95;
Cronbach’s α: 0.93), stable item locations, and good fit to the Rasch model (mean person/item fit residual: −0.21/−0.44, SD: 0.32/1.28). Estimated item
difficulty was in excellent agreement with clinical opinion (Spearman’s ρ: 0.95) and instrument scores mapped well onto health economic outcomes. We
show that the DMDSAT is a PRO instrument fit for purpose to measure functional ability in ambulant and non-ambulant patients with DMD. Rasch
analysis augments clinical expertise in the development of robust rating scales.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked
neuromuscular disease with an incidence of about one in 3800–
6300 live male births [1]. The predominant feature of DMD is
progressive muscle weakening, which at onset presents as
delayed motor milestones (e.g., running and jumping). As the
disease progresses, patients’ functional ability diminish,
resulting in loss of independent ambulation and serious
orthopaedic, cardiac, and respiratory complications [2,3]. Mean
age at death is 25 years [4], but some patients now survive to
experience their fourth decade of life.
To help track and facilitate management and monitoring of
the progression of DMD, four categories of disease (early/late
ambulatory/non-ambulatory) were proposed by the DMD Care
Considerations Working Group in the DMD care guidelines
[2,3]. However, given the considerable heterogeneity in rate of
progression and associated complications across patients with
DMD, these categories lack granularity both with respect to
applications of therapies in clinical practice, as well as
endpoints in trials. Moreover, existing clinical measures in
DMD only apply to ambulatory patients (e.g., the North Star
Ambulatory Assessment, NSAA [5,6]) or non-ambulatory
patients (e.g., the Performance of the Upper Limb, PUL [7]) or
lack sensitivity and reliability in DMD (e.g., the Vignos scale
[8] and Brooks scale [9]) and are thus not fit to map precisely
stages of disease trajectory.
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The purpose of this study was to describe the development
and initial psychometric analysis of the UK English version of
the DMD Functional Ability Self-Assessment Tool
(DMDSAT), a patient-reported outcome (PRO) scale designed
to measure and categorize functional ability across the entire
lifetime of disease progression in patients with DMD. Our aim
was to create a clinically and personally relevant tool that could
be easily completed by the patient or a caregiver (e.g., a parent)
without the assistance of a healthcare professional. To inform
health policy evaluations of DMD interventions, we also sought
to map the instrument scores to health economic outcomes,
including previously published estimates of costs of illness and
patient health-related quality of life (HRQL) [10,11].
2. Materials and methods
2.1. Instrument development
We declared the underlying latent trait to be operationalized
by the DMDSAT as “functional ability” (i.e., ability which
encompasses physical and respiratory functioning and which
describes highly relevant progression and staging of the disease
and identifies specific requirements for interventions [2,3]),
encompassing the full range within the DMD progression
sequence (i.e., from the early ambulatory to late non-
ambulatory disease stage). Given that our objective was to
create a simple tool that easily could be completed by patients
and/or their caregivers, we sought to capture the latent trait
through manifestations in common activities of daily living
(e.g., getting on and off the floor, on and off the toilet, and
climbing up and down stairs). In addition, to allow further
discrimination of functional ability, we also wanted to include
items relating to manifestations of the lower and upper
extremities, respectively, as well as ventilation status.
Given these aims, an initial set of items (questions) and
levels (response categories) was generated by a group of
neuromuscular specialists and specialist neuromuscular
physiotherapists with extensive experience in the medical
management of DMD. The list of items and their specification
was also informed by a non-systematic literature review of
existing measures. To capture the patient-perspective, items
within the draft set were discussed with and tested on patients
and caregivers in a clinical setting (as part of patients’ routine
clinical follow-up) to assure understandability (e.g., that the
items and levels made sense and were easily understood) and
completeness (e.g., that all essential levels were represented,
relevant, and appropriately formulated in terms of hierarchy).
We also conducted a pilot study, comprising five randomly
chosen patients, with follow-up questions to test the database
platform and further assure understandability and completeness.
Minor modifications were made following additional review of
items and levels by the DMD specialists.
2.2. Participants and procedures
The instrument was developed as part of a multinational,
cross-sectional study for which details and results have been
previously reported [10–12]. In summary, DMD patients from
Germany, Italy, the UK, and the US were identified through the
Translational Research in Europe – Assessment & Treatment of
Neuromuscular Diseases (TREAT-NMD) network [13]. To be
eligible, patients were required to fulfil the following criteria:
(i) Male, (ii) DMD diagnosis, and (iii) Age ≥5 years. Eligible
patients and one of their caregivers (e.g., a parent) completed a
study questionnaire comprising the DMDSAT administered
online. As the aim of this report was to validate the UK version
of the DMDSAT, only UK replies were included in the
psychometric analyses.
All participants provided informed consent. Study ethical
approval was granted from Ludwig-Maximilians-Universität
München (Germany), Comitato Etico IRCCS E. Medea –
Associazione La Nostra Famiglia (Italy), North East Research
Ethics Service, NHS (UK), and the Western Institutional
Review Board (US). Approval was also obtained from the
TREAT-NMD Global Databases Oversight Committee.
2.3. Rasch analysis
Rasch analysis was used to assess the psychometric properties
of the new instrument. Rasch analysis is the formal testing of a
scale against a mathematical model developed by the Danish
mathematician Georg Rasch [14], and is considered to be superior
to traditional psychometric methods [15]. In brief, there are
three main components to the theory of Rasch measurement.
First, a person’s response to an item is governed by two factors
only: (i) person ability (e.g., level of disease severity) and (ii)
item difficulty (i.e., the level of severity expressed by the item).
The probability that a person will affirm an item is a function
of the distance between person ability and item difficulty. The
second component is a probabilistic form of the Guttman response
pattern, which states that if a person affirms a task then there is
a high probability that easier tasks will also be affirmed (e.g.,
that a person who is able to walk longer distances would also
be expected to be able to walk short distances). The third
component to the theory of Rasch measurement is Rasch’s
criterion of invariance, which ensures that results for scales are
sample independent and results for samples are scale independent,
and is described elsewhere [15]. The Rasch analysis output
consists of an interval-level scale or metric (logit scale) to
which both respondents and items are located following the
three listed analysis components. Given good fit of the data to
the Rasch model, the interval scale allows for the meaningful
interpretation of mean total scores, as well as change in total
scores. Rasch analysis also provides a unified approach to test
several measurement issues which further helps ensure that the
scale yields meaningful, interpretable results.
2.4. Statistical analysis
We tested the psychometric properties of the DMDSAT by
analysing item and person fit to the Rasch partial credit model
(misfit defined as fit residual >|2.5| or item chi-square
Bonferroni-adjusted p-value <0.006), item dependency (i.e., if
a reply to one item predicts the reply to another item), ordering
of item response category thresholds (i.e., that respondents are
able to differentiate between response categories), reliability
(Person Separation Index [PSI], indicating the possibility of
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the scale to differentiate between respondents at different levels
of functional ability, and Cronbach’s α), targeting (i.e., the
match of the different ability levels estimated through the Rasch
model with the ability levels observed in our sample), and
item stability (i.e., differential item functioning, investigated
by glucocorticoid treatment, Bonferroni-adjusted p-value <0.002)
[15]. In addition, all instrument items were also analysed for
clinical validity and interpretability. To this end, the item thresholds
were ranked in terms of difficulty by DMD experts (n = 7),
and this order was subsequently compared with the Rasch
analysis ordering of items in terms of difficulty using Spearman’s
ρ.
We mapped the DMDSAT total scores to our previously
published estimates of costs [10] and patient HRQL (utilities)
[11] through regression analysis. Specifically, generalized
linear models with mean per-patient annual costs and mean
patient and caregiver utility as dependent variables were fitted
to the data. DMDSAT total score was the main explanatory
variable. The models were also adjusted for income class, and
common mental and behavioural disorders, as well as a dummy
variable indicating additional household member with DMD, to
control for confounding effects.
The psychometric analysis was conducted in RUMM2030
(RUMM Laboratory, Perth, Australia). All additional analyses
were conducted in Stata 12 (StataCorp LP, College Station, TX,
US).
3. Results
A total of 186 UK patients with DMD completed the
DMDSAT according to instructions together with one of their
caregivers (186 patient–caregiver pairs). Patients had a mean
age of 14 years (range 5–43) and a median age of 12 years (IQR
8–17). Approximately 45% of all patients were wheelchair
dependent and 19% required ventilation support (day and/or
night). Additional details of the study sample have been
previously published [10–12].
3.1. Psychometric properties of the DMDSAT
The administered version of the DMDSAT included a total
of eight items in four domains: Arm function, Mobility,
Transfers, and Ventilation status (Fig. 1). Two items, Arm
function and Mobility, initially displayed disordered thresholds,
indicating that participants had difficulty discriminating
between response categories given their functional ability. The
response categories for these items were consequently revised
by the DMD experts based on clinical observation and rescored
as shown in Fig. 2. Category probability curves displaying
thresholds for the Arm function item before and after rescoring
are shown in Fig. 3. A threshold map of all items is available as
supplemental material (online). Upon re-scoring, the total
DMDSAT score ranged from 0 (low functional ability) to 23
(high functional ability).
Table 1 presents the fit of the items to the Rasch model,
ordered by level of difficulty in terms of functional ability
(lower value indicates low difficulty, and vice versa). No items
displayed model misfit in terms of estimated residuals, but Get
on and off the toilet had a significant chi-square probability (due
to marginal under-discrimination). In accordance with the
ranking of item thresholds by seven international DMD
specialists, the most difficult item was Go up and down stairs,
followed by Get on and off the floor. Overall agreement
between model and expert rankings was excellent (Spearman’s
ρ = 0.95). Mean item dependency was low (−0.007), and only
two items (Get in and out of bed and Get on and off the toilet)
displayed positive correlation >0.30.
Fit of individual responses to the Rasch model was good
(mean fit residual: −0.205, SD: 0.318). Patients were evenly
distributed across elicited ability levels, floor and ceiling effects
were minimal (2% and 6%, respectively), and the estimated
scale encompassed ability levels both lower and greater than
those observed in the sample (Fig. 4). The PSI was estimated at
0.95 and Cronbach’s α at 0.93, indicating very good reliability.
The model chi-square statistic was estimated at 45, p < 0.001,
suggesting that the items did not form a unidimensional scale.
By investigating residual principal component loadings, we
found that we would obtain unidimensionality by excluding the
Arm function item (chi-square statistic 18, p = 0.208). Analysis
of scale stability showed that there was no significant uniform
or non-uniform differential item functioning by glucocorticoid
treatment (all p > 0.045 and p > 0.201, respectively).
3.2. Association between DMDSAT, total cost of illness, and
patient quality of life
The mean change in per-patient annual cost of illness
associated with a one-point increase in DMDSAT total score
was estimated at 5.3% (95% CI: 4.6%–5.9%, p < 0.001) when
Table 1
Individual item fit to the Rasch model.
Item Location (item difficulty)a SE Fit residual (observed-expected) χ2 χ2 probability
Ventilatory status −5.56 0.25 −0.20 0.34 0.846
Arm function −3.03 0.13 2.13 9.46 0.009
Get in and out of bed 0.26 0.20 −0.88 6.81 0.033
Get in and out of a chair 0.59 0.20 −1.43 6.74 0.034
Get on and off the toilet 0.71 0.20 −0.11 13.62 0.001
Mobility 1.21 0.13 −2.31 1.59 0.451
Get on and off the floor 2.28 0.18 −0.35 4.39 0.111
Go up and down stairs 3.54 0.18 −0.32 2.00 0.367
Note: Mean item fit residual = −0.435 (SD = 1.28).
a A low number represents low difficulty, and vice versa.
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adjusting for household income class, common mental and
behavioural disorders, and additional household member with
DMD. The corresponding mean loss in patient utility was 9.5%
(95% CI: 9.0%–10.1%, p < 0.001). Spearman’s ρ between
predicted and observed total cost of illness and patient utility
was estimated at 0.61 and 0.85 (p < 0.001), respectively.
Additional cost and utility analysis results are available as
supplemental material (online).
4. Discussion
In recent years, the importance of PROs from rating scales in
medical science has increased considerably [15]. The US Food
Arm function
Can put an item such as book onto a shelf above shoulder height
Can lift at least one arm above head
Can lift at least one arm to shoulder height
Can eat a meal without any help
Needs help to cut up food but can feed and drink independently
Needs help to drink or feed self
Can pick objects up e.g. pen/money
Can move fingers e.g. press on mobile or other electronic device
Cannot move fingers
Mobility
Walks independently long distances outdoors (more than 1 km)
Walks independently medium distances outdoors (less than 1 km)
Walks independently outdoors for short distances, e.g. to car
Walks outdoors with help from a person
Walks indoors independently but requires wheelchair for outdoors
Walks indoors with help from a person requires wheelchair outdoors
Uses wheelchair indoors and outdoors
Uses wheelchair but unable in some situations e.g. cold weather
Unable to control wheelchair without help
Transfers Can do
independently
Can do
with help
Needs to be lifted or
hoisted or cannot
Get on and off the floor
Get in and out of a chair
Get in and out of bed
Get on and off the toilet
Go up and down stairs
Ventilatory support Not
ventilated
Ventilated
at night
Ventilated during
day and night
Ventilatory status
The questions below describe levels of activity for arm function, mobility,
transfers, and need for ventilatory support. The activities are intended to
be in order of difficulty and we would like you to tick the box that best
applies to your current level of function.
The DMD Functional Ability Self-Assessment Tool (DMDSAT)
Select one
Select one
Fig. 1. The DMD Functional Ability Self-Assessment Tool (DMDSAT).
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and Drug Administration, for example, now require evidence in
terms of PROs in all submissions, and endpoints in clinical
trials are to a growing extent defined in terms of outcomes from
rating scales. Given their prevalence in clinical practice and
research, and their implication on health care and health policy,
it is thus critical to ensure that rating scales used are “fit for
purpose” [16].
The objective of this study was to describe the development
and Rasch analysis of the DMDSAT, a new self-assessment
rating scale measuring functional ability in patients with DMD.
During instrument development, we identified four domains
which we envisioned would capture this latent trait as
manifested in DMD: Arm function, Mobility, Transfers, and
Ventilation status. Transfers comprised five items relating to
activities of daily living, i.e., “Get on and off the floor”, “Get in
and out of a chair”, “Get in and out of bed”, “Get on and off the
toilet”, and “Go up and down stairs”. Overall, our analysis
showed that these items together successfully operationalized
functional ability in DMD, with excellent targeting and
reliability, stable item locations irrespective of glucocorticoid
treatment, and good overall fit to the Rasch model.
Initially, our Rasch analysis of the DMDSAT revealed that
two items, Arm function and Mobility, exhibited disordered
thresholds, and these were subsequently rescored for purpose of
analysis. Specifically, for Arm function, we collapsed three
categories, namely, “Can lift at least one arm above head”, “Can
lift at least one arm to shoulder height”, and “Can eat a meal
without any help”. The original scoring identified these as
distinct objectives that change over time in a given order;
however, the analysis identified a lack of progression in
difficulty indicating that e.g., a boy with DMD may find that he
can eat a meal without any help but still find bringing an arm
above his head as difficult. Thus, given the lack of distinction
between thresholds, we decided to rescore these as indicated in
Fig. 2. For the Mobility item, we collapsed three separate pairs
of items, namely, (i) “Uses wheelchair but unable in some
situations e.g. cold weather” and “Unable to control wheelchair
without help”, (ii) “Walks indoors independently but requires
wheelchair for outdoors” and “Walks indoors with help from a
person requires wheelchair outdoors”, and (iii) “Walks
independently outdoors for short distances e.g. to car” and
“Walks outdoors with help from a person”. The lack of
distinction between levels in set (i) may be explained by the fact
that both describe a boy in need of assistance for steering his
wheelchair and thus an individual who no longer is independent
in terms of mobility. For sets (ii) and (iii), although from a
clinical viewpoint they would be expected to mark different
abilities, the lack of differentiation between response categories
may reflect variability in patient preference, or possibilities to
be assisted, rather than functional ability (e.g., walk a short
distance with support from someone vs. using a wheelchair
without any help).
Upon revising the scoring algorithm for Arm function and
Mobility, the DMDSAT exhibited excellent targeting, with
good coverage of both patient abilities (top chart area, Fig. 4)
and item difficulties (bottom chart area, Fig. 4) along the
continuum. Less than 2% (3 of 186) of patients had the
minimum score and 6% (11 of 186) the maximum score, well
Arm function Original score Re-score
Can put an item such as book onto a shelf above shoulder height 8 6
Can lift at least one arm above head 7
5Can lift at least one arm to shoulder height 6
Can eat a meal without any help 5
Needs help to cut up food but can feed and drink independently 4 4
Needs help to drink or feed self 3 3
Can pick objects up e.g. pen/money 2 2
Can move fingers e.g. press on mobile or other electronic device 1 1
Cannot move fingers 0 0
Mobility Original score Re-score
Walks independently long distances outdoors (more than 1 km) 8 5
Walks independently medium distances outdoors (less than 1 km) 7 4
Walks independently outdoors for short distances, e.g. to car 6
3
Walks outdoors with help from a person 5
Walks indoors independently but requires wheelchair for outdoors 4
2
Walks indoors with help from a person requires wheelchair outdoors 3
Uses wheelchair indoors and outdoors 2 1
Uses wheelchair but unable in some situations e.g. cold weather 1
0
Unable to control wheelchair without help 0
Fig. 2. DMDSAT arm function and mobility item scoring structure. Note: Transfer/Ventilatory support items were scored 0 = Can do independently/Not ventilated;
1 = Can do with help/Ventilated at night; and 2 = Needs to be lifted or hoisted or cannot/Ventilated during day and night.
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below proposed upper limits for floor and ceiling effects of 15%
and 20% [14]. The Rasch analysis also showed that the
DMDSAT had very good reliability. Specifically, the PSI was
estimated at 0.95, which means that our construct can
differentiate between five groups of responders, and
Cronbach’s α at 0.93, markedly higher than the recommended
thresholds of 0.70 and 0.80 [15]. We also noted excellent
agreement between the Rasch model and expert rankings of
item thresholds in terms of difficulty, supporting the clinical
validity and interpretation of the DMDSAT total scores.
In the analysis, we identified a positive dependency between
two items, namely, Get in and out of bed and Get on and off the
toilet. The correlation may be explained by similarity in the
physical ability required to perform the tasks. However, upon
removing one of the items, the PSI changed only by 0.007
(<0.8%), indicating that this dependency did not artificially
inflate reliability. From a clinical point of view, given the
different muscles involved in e.g., getting out of bed and off the
toilet, and also because the tasks encompass different spheres of
life (independence inside vs. outside of the home), including
both items was deemed justified.
Although our analysis demonstrated that fit of all items to
the Rasch model was good, we noted that unidimensionality
(which is a requirement for interval measures) could be
improved by removing the Arm function item. This finding
suggests that Arm function also measures a latent trait other
than functional ability, which is certainly possible given the
variation in disease manifestations both between and within
patients and stages of DMD progression. In addition, using
modern technology, a patient not able to move his fingers may
in fact be able to control a wheelchair without any help,
complicating the interpretation of the hierarchical relationship
of item thresholds in terms of functional ability. Moreover, for
some patients, reduced functional ability of the upper
extremities may not be apparent until they are dependent on
wheelchairs for mobility, but may already be present whilst they
are ambulant. For these reasons, and given our objective to
capture total function rather than disjointed function of arms
and legs separately, we decided to retain Arm function in the
scale, also as it contributed substantially to differentiating
between respondent abilities, in particular among the less able
boys. However, given that the other tests displayed good fit to
0
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B
Fig. 3. Category probability curves for arm function, before (A) and after (B) rescoring. Note: As shown in panel A, respondents had difficulty discriminating
between response categories 5, 6, and 7 (5 = “Can lift at least one arm above head”, 6 = “Can lift at least one arm to shoulder height”, and 7 = “Can eat a meal without
any help”). For purpose of analysis, these categories were collapsed into a single category (category 5 in panel B).
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the Rasch model, the impact of this issue in terms of
interpreting total DMDSAT scores would be expected to be
minor. Additional analysis of the relationship between arm and
leg functions in DMD is needed to further validate clinical and
patient rating scales.
We estimated the mean change in annual cost of illness per
one-point increase in DMDSAT total score at 5.3%, and a mean
loss in patient utility of 9.5%. These estimates should be helpful
to inform cost-effectiveness analysis of DMD interventions, in
particular model frameworks where progression and health
states are defined in terms of DMDSAT scores, which will
allow for more differentiated assessments as compared to e.g.,
the early/late ambulatory/non-ambulatory classes. Moreover,
given that the DMDSAT was developed as a complement to
existing scales in an attempt to add granularity not only to trial
assessments but also to assignment of care standards to
different disease stages, the scale should have utility in many
different settings, including clinical practice, research, and
health policy.
The strengths of our study include the comparably large
sample of DMD patients, who usually are very difficult to
identify due to the rarity of the disease, encompassing an
extensive range of disease severity (i.e., levels of functional
ability), as well as the comprehensive Rasch analysis (deemed
superior to traditional psychometric analysis [15]). The main
limitation of our study concerns generalizability, as our patient
sample was recruited through the TREAT-NMD network and it
is not known to what extent this population is representative of
all DMD patients in the UK (although differences in terms of
clinical manifestations would be expected to be very minor). It
should also be noted that future research is needed to further
validate the DMDSAT and assess properties such as
responsiveness, test–retest reliability, and minimally important
difference thresholds.
In summary, we show that the DMDSAT is a PRO
instrument fit for purpose to measure functional ability in
ambulant and non-ambulant patients with DMD. It
complements existing clinical rating scales and map well onto
health economic outcomes in this population. Rasch analysis
augments clinical expertise in the development of robust rating
scales.
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